BIOMARIN PHARMACEUTICAL INC's ticker is and the CUSIP is 09061GAF8. A total of 40 filers reported holding BIOMARIN PHARMACEUTICAL INC in Q1 2019. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q4 2019 | $551,000 | +5.6% | 5,060 | 0.0% | 0.01% | +25.0% |
Q3 2019 | $522,000 | -8.3% | 5,060 | 0.0% | 0.00% | 0.0% |
Q2 2019 | $569,000 | -1.2% | 5,060 | 0.0% | 0.00% | -20.0% |
Q1 2019 | $576,000 | +2.1% | 5,060 | 0.0% | 0.01% | 0.0% |
Q4 2018 | $564,000 | -7.5% | 5,060 | 0.0% | 0.01% | 0.0% |
Q3 2018 | $610,000 | +1.3% | 5,060 | 0.0% | 0.01% | 0.0% |
Q2 2018 | $602,000 | +7.5% | 5,060 | 0.0% | 0.01% | +25.0% |
Q1 2018 | $560,000 | -7.9% | 5,060 | 0.0% | 0.00% | -20.0% |
Q3 2017 | $608,000 | -27.9% | 5,060 | -28.3% | 0.01% | -37.5% |
Q2 2017 | $843,000 | +0.7% | 7,060 | 0.0% | 0.01% | +14.3% |
Q1 2017 | $837,000 | +0.7% | 7,060 | 0.0% | 0.01% | 0.0% |
Q4 2016 | $831,000 | -6.0% | 7,060 | 0.0% | 0.01% | -22.2% |
Q3 2016 | $884,000 | -36.9% | 7,060 | -41.5% | 0.01% | -10.0% |
Q2 2016 | $1,400,000 | -2.5% | 12,060 | 0.0% | 0.01% | 0.0% |
Q1 2016 | $1,436,000 | -11.2% | 12,060 | 0.0% | 0.01% | -9.1% |
Q4 2015 | $1,618,000 | – | 12,060 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Birch Grove Capital LP | 5,000,000 | $5,003,000 | 2.71% |
Weiss Asset Management LP | 65,841,000 | $64,360,000 | 2.62% |
Davide Leone & Partners Investment Co Ltd. | 10,500,000 | $10,513,000 | 1.19% |
TENOR CAPITAL MANAGEMENT Co., L.P. | 29,597,000 | $29,800,000 | 1.14% |
GLAZER CAPITAL, LLC | 7,483,000 | $7,474,000 | 0.36% |
BLUEFIN CAPITAL MANAGEMENT, LLC | 52,500 | $5,243,000 | 0.33% |
OAKTREE CAPITAL MANAGEMENT LP | 13,428,000 | $13,444,000 | 0.29% |
CSS LLC/IL | 5,500,000 | $5,498,000 | 0.26% |
Kohlberg Kravis Roberts & Co. L.P. | 40,182,000 | $40,159,000 | 0.23% |
EDMOND DE ROTHSCHILD HOLDING S.A. | 2,606,000 | $2,606,000 | 0.10% |